Skip to main content
Clinical Trials/NL-OMON44266
NL-OMON44266
Completed
Not Applicable

Observational multi-center, prospective study to develop a novel multi-parametric diagnostic model for hospitalized patients and patients on the Emergency Department presenting with lower respiratory tract infections and/ or sepsis. - The TAILORED-treatment Study

niversitair Medisch Centrum Utrecht0 sites467 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
sepsis en virale infecties
Sponsor
niversitair Medisch Centrum Utrecht
Enrollment
467
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
June 27, 2016
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
niversitair Medisch Centrum Utrecht

Eligibility Criteria

Inclusion Criteria

  • Patients (children and adults) who are at least 1 month old of age that attend the hospital or the ED due to suspected respiratory infections and/or sepsis (whose onset of symptoms began \* 8 days prior of recruitment) or due to a non\-infectious desease, will be eligible for inclusion.;\-The LRTI disease group should fulfill the following criteria:
  • Presence of two or more of the following signs of respiratory distress:
  • \-Tachypnea \*
  • \-(Chest)Cough
  • \-Nasal flaring
  • \-Retractions
  • \-Expiratory wheeze and/or decreased breath sounds;\* (WHO age\- specific criteria for tachypnea wil be used: a respiratory rate of more than 50 breaths per minute in infants 2\-12 months of age; more than 40 breaths per minute in children 1\-5 years of age; and more than 30 breaths in children older than 5 years);\-The Sepsis group should fulfill the following criteria:
  • Sepsis will be defined as a combination of a systemic inflammatory response syndrome (SIRS) due to infectious agent. SIRS will be determined according to published criteria (the International Sepsis Definitions Conference, 2001\) based on
  • \-Heart rate (higher than 90/min)
  • \-Respiratory rate (higher than 20/min or PaCO2 lower than 32 mmHg)

Exclusion Criteria

  • \-An episode of febrile infection during the past 3 weeks
  • \-A proven or suspected human immunodeficiency virus (HIV)\-1, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection
  • \-Presence of obvious alternative causes of respiratory distress, such as heart failure or pneumothorax
  • \- Patiënten met een nosocomiale LRTI (developed \> 3days after hospitalization)
  • \-Post\-transplant patients
  • \-Congenital immune deficiency (CID)
  • \-Active hematological malignancy
  • \-Current treatment with immune\-suppressive or immune\-modulating therapies including:
  • \* \-Chemotherapy
  • \* \-Radiotherapy

Outcomes

Primary Outcomes

Not specified

Similar Trials